US 12,227,757 B2
Methods and products for transfecting cells
Matthew Angel, Cambridge, MA (US); and Christopher Rohde, Cambridge, MA (US)
Assigned to Factor Bioscience Inc., Cambridge, MA (US)
Filed by Factor Bioscience Inc., Cambridge, MA (US)
Filed on Aug. 5, 2022, as Appl. No. 17/817,966.
Application 17/817,966 is a continuation of application No. 16/567,059, filed on Sep. 11, 2019, granted, now 11,466,293.
Application 16/567,059 is a continuation of application No. 16/402,175, filed on May 2, 2019, granted, now 10,472,611, issued on Nov. 12, 2019.
Application 16/402,175 is a continuation of application No. 15/429,795, filed on Feb. 10, 2017, abandoned.
Application 15/429,795 is a continuation of application No. 15/222,453, filed on Jul. 28, 2016, granted, now 9,605,278, issued on Mar. 28, 2017.
Application 15/222,453 is a continuation of application No. 14/296,220, filed on Jun. 4, 2014, granted, now 9,422,577, issued on Aug. 23, 2016.
Application 14/296,220 is a continuation of application No. PCT/US2012/067966, filed on Dec. 5, 2012.
Claims priority of provisional application 61/664,494, filed on Jun. 26, 2012.
Claims priority of provisional application 61/637,570, filed on Apr. 24, 2012.
Claims priority of provisional application 61/569,595, filed on Dec. 12, 2011.
Claims priority of provisional application 61/566,948, filed on Dec. 5, 2011.
Prior Publication US 2023/0033888 A1, Feb. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/85 (2006.01); A61K 35/28 (2015.01); C08K 5/5399 (2006.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 5/0789 (2010.01); C12N 9/16 (2006.01); C12N 9/22 (2006.01); C12N 15/87 (2006.01); C12N 15/90 (2006.01); C12P 21/00 (2006.01); H01L 31/048 (2014.01); A61K 35/12 (2015.01); C08G 77/08 (2006.01)
CPC C12N 15/87 (2013.01) [A61K 35/28 (2013.01); C08K 5/5399 (2013.01); C12N 5/0647 (2013.01); C12N 5/0657 (2013.01); C12N 5/0696 (2013.01); C12N 9/16 (2013.01); C12N 9/22 (2013.01); C12N 15/907 (2013.01); C12P 21/00 (2013.01); C12Y 301/21 (2013.01); H01L 31/048 (2013.01); A61K 2035/124 (2013.01); C08G 77/08 (2013.01); C12N 2500/25 (2013.01); C12N 2500/44 (2013.01); C12N 2501/115 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/26 (2013.01); C12N 2501/91 (2013.01); C12N 2501/998 (2013.01); C12N 2506/09 (2013.01); C12N 2800/80 (2013.01); Y02E 10/50 (2013.01)] 20 Claims
 
1. A method for producing a gene-edited and reprogrammed cell, comprising:
(a) providing a differentiated cell;
(b) culturing the differentiated cell; and
(c) transfecting the differentiated cell with at least one RNA molecule encoding one or more gene-editing proteins, resulting in the differentiated cell expressing the one or more gene-editing proteins, thereby gene-editing the differentiated cell to produce a gene-edited cell; and
(d) transfecting the gene-edited cell of (c) with at least one RNA molecule encoding one or more reprogramming factors, resulting in the gene-edited cell expressing the one or more reprogramming factors;
thereby producing a gene-edited and reprogrammed cell;
wherein (d) occurs in the presence of a medium containing ingredients that support reprogramming of the gene-edited cell to a less differentiated state.